Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Gun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of Interest'Science Spin' Found Prevalent in Biomedical LiteratureHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening CompletionMany Americans Getting Medical Care They Don't NeedInsurer Aetna's Envelopes Revealed Customers' HIV StatusHealth Groups Demand 'R' Rating for Movies That Show SmokingGoogle Search for 'Depression' Now to Provide Screening TestPatients' Hearing Loss May Mean Poorer Medical CareFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?Steep Price Hikes Led to Drop in Use of 2 Heart Drugs at U.S. HospitalsAPA: Medical Discrimination Based on Size Stresses Patients2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryMedical Reality Catches Up to Science FictionFDA Looks to Reduce Nicotine in CigarettesAHA Hands-Only CPR Training Kiosks Available at More Airports$100 Sweetens the Pot for a ColonoscopyJust a Few Vaccine Refusers Could Endanger ManyASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: StudyPatient Involvement Can Cut Errors in X-Ray ImagingMarket Competition Linked to Change in Generic Drug Prices
Questions and AnswersLinksBook Reviews
Related Topics

Market Competition Linked to Change in Generic Drug Prices


HealthDay News
Updated: Jul 6th 2017

new article illustration

THURSDAY, July 6, 2017 (HealthDay News) -- Market competition levels are associated with changes in the price of generic drugs, according to a study published online July 4 in the Annals of Internal Medicine.

Chintan V. Dave, Pharm.D., from the University of Florida in Gainesville, and colleagues conducted a retrospective study involving prescription claims for commercial health plans from 2008 to 2013. They calculated the Herfindahl-Hirschman Index (HHI) by summing the squares of individual manufacturers' market shares for each six-month period, with higher values indicating a less competitive market. In each period, the authors estimated the average drug prices for generic drugs. The HHI value estimated in the first half of 2008 was modeled as a fixed covariate.

The researchers identified a cohort of 1,120 generic drugs from 1.08 billion prescription claims. Price changes of −31.7, −11.8, 20.1, and 47.4 percent were seen for drugs with quadropoly (HHI value of 2,500), duopoly (HHI value of 5,000), near-monopoly (HHI value of 8,000), and monopoly (HHI value of 10,000) levels of baseline competition, respectively, over the study period.

"Market competition levels were associated with a change in generic drug prices," the authors write. "Such measurements may be helpful in identifying older prescription drugs at higher risk for price change in the future."

Abstract/Full Text (subscription or payment may be required)